Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.

Clinical lung cancer - 1 Jul 2021

Yu Hui, Brustugun Odd Terje, Ekman Simon, Botling Johan, La Fleur Linnea, Micke Patrick, Solberg Steinar, Berglund Anders, Rivard Christopher, Hirsch Fred R

Abstract excerpt

BACKGROUND: Recently, anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapies have yielded promising outcomes for patients with advanced non-small cell lung cancer (NSCLC) and led to great interest in applying these agents to treat resectable early-stage NSCLC. The objective of our study was to evaluate PD-L1 protein expression in resectable early-stage NSCLC specimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Neoplasm Staging

Share to Norway

Share to Proto-Oncogene Proteins p21(ras)

Share to Sweden

Source

Identifiers

PMID: 33214079
DOI: 10.1016/j.cllc.2020.09.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.PMID 33214079Read ↗

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Semantic proximity Read ↗

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.Semantic proximity Read ↗

Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.Semantic proximity Read ↗

Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.Semantic proximity Read ↗

Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non-Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience.Semantic proximity Read ↗

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with ChemotherapySemantic proximity Read ↗

Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.Semantic proximity Read ↗

PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.Semantic proximity Read ↗

PD-L1 expression is not a predictive factor for recurrence in resected non-small cell lung cancer Sub-heading: PD-L1 is not a predictive factor for recurrenceSemantic proximity Read ↗

Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.Semantic proximity Read ↗

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.